Login / Signup

Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome.

Eamonn M M QuigleyLouise MarkinsonAlex StevensonF Peter TreasureBrian E Lacy
Published in: Alimentary pharmacology & therapeutics (2022)
gov #NCT03721107.
Keyphrases
  • irritable bowel syndrome
  • clinical trial
  • open label
  • double blind
  • phase ii
  • study protocol
  • phase iii
  • placebo controlled